Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Multivalent Pneumococcal Vaccine - Formulation 1
Multivalent Pneumococcal Vaccine · 1 trial · 1 indication
Prespecified local reactions (redness, swelling, and pain at the injection site) after vaccination
Prespecified systemic events (fever, headache, fatigue, muscle pain, and joint pain) after vaccination
Adverse events occurring within 1 month after vaccination
SAEs occurring within 6 months after vaccination
Related SAEs occurring through 12 months after vaccination
| Arm | Type | Description |
|---|---|---|
| Phase 2 (Stage 4): Multivalent Pneumococcal Vaccine - Formulation 3 | EXPERIMENTAL | Participants to receive a single injection of Multivalent Pneumococcal Vaccine - Formulation 3. |
| Phase 1 (Stage 1): Multivalent Pneumococcal Vaccine - Formulation 1 | EXPERIMENTAL | Participants to receive a single injection of Multivalent Pneumococcal Vaccine - Formulation 1. This is a possible candidate for continuation in Phase 2 (Stage 2, 3, and 4). |
| Phase 1 (Stage 1) and Phase 2 (Stage 2): 20-valent pneumococcal conjugate vaccine (20vPnC) | ACTIVE_COMPARATOR | Participants to receive a single injection of 20vPnC. |
| Phase 1 (Stage 1): Multivalent Pneumococcal Vaccine - Formulation 2 | EXPERIMENTAL | Participants to receive a single injection of Multivalent Pneumococcal Vaccine - Formulation 2. This is a possible candidate for continuation in Phase 2 (Stage 2, 3, and 4). |
| Phase 2 (Stage 3): a licensed pneumococcal comparator vaccine | ACTIVE_COMPARATOR | Participants to receive a single injection of a licensed pneumococcal comparator vaccine. |
| Phase 2 (Stage 4): Multivalent Pneumococcal Vaccine - Formulation 4 | EXPERIMENTAL | Participants to receive a single injection of Multivalent Pneumococcal Vaccine - Formulation 4. |
| Name | Type | Description |
|---|---|---|
| Multivalent Pneumococcal Vaccine - Formulation 1 | BIOLOGICAL | Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stages 2, 3, and 4). |
| Multivalent Pneumococcal Vaccine - Formulation 2 | BIOLOGICAL | Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stages 2, 3, and 4). |
| 20-valent pneumococcal conjugate vaccine (20vPnC) | BIOLOGICAL | 20-valent pneumococcal conjugate vaccine (20vPnC) |
| Licensed pneumococcal comparator vaccine | BIOLOGICAL | A licensed pneumococcal comparator vaccine |
| Multivalent Pneumococcal Vaccine - Formulation 3 | BIOLOGICAL | Multivalent pneumococcal conjugate vaccine |
| Multivalent Pneumococcal Vaccine - Formulation 4 | BIOLOGICAL | Multivalent pneumococcal conjugate vaccine |
Inclusion Criteria: * Male or female participants ≥18 to\<50 years of age (Stage 1) and ≥50 years of age (Stage 2, Stage 3, and Stage 4) at the time of consent * Adults determined by clinical assessment to be eligible for the study, including adults with preexisting stable disease within 12 weeks b...
The Multivalent Pneumococcal Vaccine is an investigational vaccine developed by Pfizer for the prevention of pneumococcal disease. It is designed to stimulate an immune response against pneumococcal bacteria and is currently in Phase 1 clinical development. It has been studied in healthy adult volunteers aged 18 years and older.
The Multivalent Pneumococcal Vaccine is being developed for the prevention of pneumococcal disease, an infectious condition caused by Streptococcus pneumoniae bacteria. It is intended for use in adults 18 years of age and older. The vaccine remains investigational and has not been approved for commercial use.
Pfizer, Inc. is developing the Multivalent Pneumococcal Vaccine. Pfizer trades on the New York Stock Exchange under the ticker symbol PFE. The company is the sole developer listed for this vaccine candidate, which is being studied for the prevention of pneumococcal disease in adults.
The Multivalent Pneumococcal Vaccine is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this candidate.
The Multivalent Pneumococcal Vaccine has been evaluated in one completed Phase 1 trial, NCT06182124, titled A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults. The trial enrolled 1,710 healthy adult volunteers in the United States and was randomized, double-blind, and active-controlled.
Yes. The Multivalent Pneumococcal Vaccine is also known as Multivalent Pneumococcal Vaccine - Formulation 1, and the alternate spelling Multivalent Pneumococcal Vaccine- Formulation 1 refers to the same Pfizer vaccine candidate. These names describe the same investigational product being studied for pneumococcal disease prevention.